Eyenovia Optejet Device

Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, brings human-centric design to ophthalmology with its novel Optejet® dispenser. 

Traditional eye drops normally overdose the patient's eye with medication and preservatives. Eyenovia's easy-to-use, novel Optejet® dispenser administers precisely 8µL of medication to the eye, effectively treating the patient's condition while creating a more gentle dosing experience. 

"The unique delivery mechanism of the Optejet® will fundamentally change how we think about eye medication," said Michael Rowe, CEO of Eyenovia. "Right now, traditional eye drops can result in significant dose-related side effects for the treatment of chronic illnesses like glaucoma. The Optejet® dispenser is designed for patients to experience easier administration and fewer side effects with similar efficacy."

The Optejet® dispenser administers ophthalmic solutions horizontally using Eyenovia's proprietary Microdose Array Print (MAP™) technology. The system functions similar to an inkjet printer, delivering accurate microdoses through a precision spray. Traditional eye drops deliver four to five times larger volume than the human eye can actually hold, which causes eye drops to roll down the face and overdose the eye with preservatives. 

Poor delivery of eye drops is more than an inconvenience; it can prevent patients from using necessary medication because of the side effects. For example, with medication to help dilate the pupils for eye exams, up to 23% of patients experienced stinging and burning with the eye drops, causing patients to forgo eye exams. In Eyenovia studies, less than 1% of patients experienced stinging and burning. 

"Medications only work if patients take them, and with the Optejet, we have designed a way for patients to benefit from an easy-to-use, appropriate, lower dose spray that results in similar efficacy. We're excited for physicians and providers to be able to offer this revolutionary technology in the near future to patients who deserve a more positive experience," said Rowe.

Eyenovia's first marketed invention is expected to be MydCombi™, a first-in-class drug-device combination microdose for in-office pupil dilation. This potentially will help save physician's chair time, eliminating the traditional three eyedrops used for a patient's eye exam. Other exciting innovations in the Eyenovia pipeline include MicroLine (for the treatment of Presbyopia) and MicroPine (for the treatment of Myopia).

For more information, visit eyenovia.com.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia, and myopia progression. For more information, visit www.eyenovia.com.

Forward-Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents that we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws. Eyenovia does not undertake any obligation to update any forward-looking statements.

Eyenovia Contact:

Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
[email protected]

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
[email protected]
(646) 751-4363

Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
[email protected]

MadgeTech, a leading data logger manufacturer, announces the expanded temperature range of the HiTemp140-FP data logger with the ability to monitor and record temperatures from -200 °C to +260 °C (-328 °F to +500 °F).

Designed for high-temperature applications, including autoclave validation, food processing, and mapping studies, the HiTemp140-FP is made of stainless steel and features an RTD sensor with PFA insulated cable, available in lengths from six to 72 inches. All probe lengths are available with either a stainless-steel tip for easy placement into vials or test tubes, or a bare version for use with accessories such as the CF200 for canning application or the MicroDisc for surface temperature monitoring. 

The expanded temperature range now enables the HiTemp140-FP to monitor temperatures as low as -200 °C (-328 °F), making it a multi-use solution for both high and low temperatures. The body of the HiTemp140 can withstand temperatures from -40 °C to +140 °C (-40 °F to +284 °F)

For more information on the HiTemp140-FP, please contact MadgeTech at [email protected]. 

About MadgeTech
Headquartered in Warner, New Hampshire, MadgeTech has over 25 years of experience in the engineering and manufacturing of data loggers. As an ISO 9001 company, MadgeTech is built on the founding principles of quality, customer satisfaction, and consistent improvement. MadgeTech offers a range of data loggers capable of measuring over 10 different parameters and features an in-house ISO 17025 certified calibration laboratory. 

Novant Health, one of the largest healthcare systems in the Southeast, has significantly improved its patient financial experience by partnering with Cedar, an enterprise healthcare engagement platform that improves the end-to-end consumer financial journey. By investing in Cedar Pay, Cedar's post-visit billing and payment platform, Novant Health continues to lead the way when it comes to bringing digital innovation to the revenue cycle.

For years, Novant Health had worked to modernize their revenue cycle organization, leaning on mail, email and EHR communications to reach patients. While these initiatives drove incremental improvements, the health system identified two key opportunities in 2019 to truly enable a more consumer-centric experience for their patients:

1. Combining Novant Health's acute and ambulatory services into a single billing experience. While the organization had tried to combine physician and facility billing for years, they had always been met with pushback from vendors or complex EHR upgrades that could fundamentally break their existing processes. 
    
2. Making bill payment a low friction, easy to navigate experience for both patients and team members. Novant Health wanted to help patients understand how their payments work and how their insurance benefits applied. In order to do so, they needed to personalize the experience, using mobile technology that consumers were already familiar with. 

To address these challenges, Novant Health invested in Cedar Pay. Cedar Pay delivers personalized billing through outreach, messaging and bill resolution based on a variety of unique factors and preferences. The platform is fully integrated with Novant Health's existing Epic EHR system across both hospital billing and physician billing. 

As a result of their implementation of Cedar Pay, Novant Health has seen a material rise in collections over a 12-month period, amounting to tens of millions of dollars, as well as: 

• 90% patient satisfaction score
• 87% of collections now completely self-serviced
• 43% drop in days to collect

"Investing in a consumer engagement platform like Cedar is something we had wanted to do for a long time as part of our digital transformation strategy—we wanted to create a singular financial experience that allows our patients to pay with the technology we keep in our pockets," said Geoff Gardner, senior vice president of Finance at Novant Health. "Cedar has been a great partner to us in our commitment to delivering a remarkable healthcare experience to our community; the results truly speak for themselves, as we have been able to increase collections while also improving patient satisfaction." 

"At Cedar, we know that engaged, happy patients lead to better outcomes, and the best way to improve patient satisfaction is by implementing consumer-friendly technology," said Florian Otto, CEO and co-founder of Cedar. "It's been a privilege working with such an innovative health system like Novant Health, and we look forward to continuing our partnership and continuing to impact the lives of their patients." 

To learn more about how Novant Health has seen a 9x ROI through its strategic partnership with Cedar, read the full case study here.

About Cedar

Cedar is committed to improving the healthcare billing experience for all. With an innovative platform that connects providers and payers, Cedar empowers healthcare consumers with a personalized journey—all powered by data science and interactive design. For Cedar clients, this leads to increased collections, more efficient operations and greater consumer loyalty. To learn more about why leading U.S. healthcare organizations trust Cedar to manage the end-to-end consumer experience from pre-registration to post-visit billing, visit www.cedar.com and join us on LinkedIn, Twitter, Facebook and YouTube.

About Novant Health

Novant Health is an integrated network of physician clinics, outpatient facilities and hospitals that delivers a seamless and convenient healthcare experience to communities in North Carolina, South Carolina, Virginia and Georgia. The Novant Health network consists of more than 1,800 physicians and over 35,000 employees who provide care at nearly 800 locations, including 15 hospitals and hundreds of outpatient facilities and physician clinics. In 2021, Novant Health was the highest-ranking healthcare system in North Carolina to be included on Forbes' Best Employers for Diversity list. Diversity MBA Magazine ranked Novant Health first in the nation on its 2021 list of "Best Places for Women & Diverse Managers to Work." In 2020, Novant Health provided more than $1.02 billion in community benefit, including financial assistance and services.

For more information, please visit our website at NovantHealth.org. You can also follow us on Twitter and Facebook.

Contact

For Cedar
Jenny Fiegoli
PR & Communications Manager
[email protected] 

For Novant Health
Novant Health media relations
844-536-3288 (this number does not accept text messages)
[email protected]

MEDHOST
logo

MEDHOST®, a leading EHR (electronic health record) and healthcare IT solutions provider, now offers MEDTEAM™ Solutions, a broader range of expanded services, including revenue cycle solutions and staffing, day-to-day support including IT, help desk and security, managed integrations, application configuration and management, and health IT education services for healthcare organizations of all types and sizes.

Today, increased complexities of delivering healthcare combined with staffing challenges and mounting regulations have forced healthcare providers to seek a greater operating scale. This includes stronger support and more complex operations to acquire and retain specialized human resources. These challenges have, in many instances, made outsourcing financial and operating processes the most effective strategy. To support MEDHOST's mission of promoting customer success, MEDHOST has consolidated and expanded its existing business services under a renamed MEDTEAM corporate umbrella. Matthew Higgins, Chief Financial Officer of MEDHOST, has been named President of MEDTEAM Solutions.

"MEDHOST has always been focused on helping our customers take care of the communities they serve while attaining financial, clinical and operational success," said Ken Misch, President of MEDHOST. "Under Matthew's leadership, MEDTEAM Solutions will enable us to offer more comprehensive services to meet their current and future needs."

MEDTEAM Solutions provides the following services to help facilities succeed clinically, financially, and operationally:

• Revenue Cycle Management - Designed to improve cash flow, increase reimbursements, and accelerate revenue with fewer disruptions from staffing shortages by leveraging Claims Reimbursement and Contract Management services.
• Application Management, Content, and Configuration Services - Experienced HIT system application specialists provide world-class support and help optimize the end-user experience and improve financial performance.
• Managed Integration Services- Avoid the costs of building and maintaining complex integrations by utilizing fully-managed cloud-based services, including support of independent data exchange and interface requirements.
• Information Security Services - Access to virtual security experts helps alleviate an industry shortage of infosec professionals.
• Education Services - Setting up healthcare facilities for continued success with virtual or live, on-demand education and training services for HIT applications and processes.

"The MEDTEAM offerings are crafted to meet existing and forthcoming needs of healthcare providers," says Matthew Higgins, President of MEDTEAM Solutions. "MEDTEAM Solutions fills the gap in affordable service offerings that community healthcare facilities need. Having the ability to combine the shared goal of providing exceptional patient care with effective business practices is critical for providers to meet their clinical, financial, and operational objectives."

To learn more about how MEDTEAM Solutions can help healthcare facilities to continue to excel in delivering care and financial success, please reach out to 1.844.615.1803 or [email protected]

About MEDTEAM Solutions, Inc.

MEDTEAM has been providing services to over 200 healthcare facilities of all types and sizes nationwide, partnering with them to help accelerate their clinical, financial, and operational success. Its services include revenue cycle management, application configuration and management, integration management, information security services, and education and training. Connect with MEDTEAM Solutions on Twitter, Facebook, and LinkedIn.

About MEDHOST

MEDHOST has provided products and services to healthcare facilities of all types and sizes for over 35 years. Today, facilities nationwide are partnering with MEDHOST to enhance their patient care and operational excellence with its clinical and financial solutions, which include an integrated EHR solution. Our solutions make it easy to focus on what's important for healthcare facilities: their patients and business.

Connect with MEDHOST on Twitter, Facebook and LinkedIn.

Media Inquiries

Samra Khan
Senior Marketing Manager
[email protected]

Imagene, an emerging leader in the field of AI-based precision oncology, today announced a collaborative research with the pathology department at the Tel Aviv Sourasky Medical Center. The research "Image-based identification of HER2 status in H&E-stained breast cancer slides" was selected to be presented at the European Congress of Pathology (ECP), Sept. 3-7, 2022, Basel, Switzerland. 

Breast cancer treatment is based, among other, on the Human Epidermal growth factor Receptor 2 (HER2) status. Current methodologies for HER2 testing rely on immunohistochemistry (IHC) followed by analysis using in situ hybridization (ISH) techniques in equivocal (score 2) cases. The interpretation of those conventional methodologies is limited due to the subjective nature of the method. Thus, major differences are seen between pathologist analysis or different medical centers since IHC scoring is based on a signal quantification that, in most cases, is done manually. Discrepancies can be as broad as 50% in close categories (score 1 vs. 2, score 2 vs. 3, etc.).

Imagene developed a deep learning algorithm to directly infer HER2 status in real-time from an H&E-stained slide image alone. In this research, the HER2-classifier was tested on a cohort of 635 patients, revealing 83% sensitivity and 79% specificity, with an Area Under Curve (AUC) of 0.88. Importantly, analysis of the results revealed that 50% of the "false positive" cases originated from the newly HER2-low classification; therefore, the reported accuracy is even higher in real practice, considering the new HER2 low class (HER2 score 1&2-non-amp) that were recently approved by the FDA for targeted treatment.

These results present, to the best of our knowledge, the highest accuracy metrics of HER2 detection reported so far; furthermore, it emphasizes the fact that the AI model pointed to crucial biological features even before they were formally defined, such as the HER2-low classification. The ability to use image-based detection for HER2 inference may pose superior diagnostic and classification, especially in domains where human interpretation and subjective tests are being applied. 

"AI-based image analysis algorithms show promise in identifying molecular characteristics of the tumor directly from the microscopic images. This requires simultaneous quantitative analysis of multiple morphological parameters and cannot be done by human pathologists," said Prof. Dov Hershkovitz, Director of the Pathology Dept., Sourasky Medical Center. "I believe Imagene's technology is going to change the way we practice pathology and perform biomarker analysis."

"Complex diseases with multiple genomic alterations such as cancer urges us to adopt advanced new analysis tools that can deal with such levels of complexity,'' said Dr. Nurit Paz-Yaacov, Chief Scientific Officer at Imagene. "We are grateful for the tight research collaboration with the Tel Aviv Sourasky Medical Center; by working together, we ensure that innovation and new technologies are meeting real clinical practice challenges." 

Dr. Greenberg will present the research on September 6, 9:20 AM (CET). Imagene's scientific team and Sourasky Medical Center pathologists will also be available for individual presentations in booth #6, September 3-7 at the Congress Center, Basel, Switzerland.

Imagene's deep learning models have been shown to detect a wide range of cancer biomarkers in real-time, using only a digitally scanned Hematoxylin and Eosin (H&E) image. Imagene's molecular classifiers currently detect 28 different cancer biomarkers, spanning eight organs, including lung, thyroid, breast, ovary, CNS, bladder, colon, and hematologic malignancies. When compared to gold standard testing methods, Imagene's validation demonstrated, on average, sensitivity of 94.8%, greater than 90% specificity, and an AUC of over 0.95. Imagene has demonstrated the capability to identify a spectrum of alterations, including differential gene expression (e.g. HER2 presented here), mutations (e.g., EGFR), fusions and other structural variants (e.g., NTRK), and cancer signatures (e.g., HRD).

ABOUT IMAGENE
Imagene AI is a precision oncology diagnosis company. Its molecular and spatial intelligence platform delivers real-time biomarker reports using only digitized biopsy images, leading to faster diagnosis and better identification of treatment targets for patients. Its multidisciplinary team is composed of a diverse group of experts from the fields of science, medicine, and deep learning. 
Imagene collaborates with top-tier medical centers and pharmaceutical companies worldwide, striving to render therapeutic decisions for cancer patients more accurate and accessible, profiling patients for clinical trials, and accelerating the drug development process.
For more information, visit Imagene-AI.com.

The mentioned products are currently in Research Use Only (RUO) and subject to regulatory clearances in the applicable markets.

Media contact
Avital Rabani
Head of Marketing, Imagene
[email protected]